KÔL at ESCRS 2026 From 11 to 15 September 2026, KÔL was in London for the 44th ESCRS Congress at ExCeL London. The team was there for several days of meetings and discussions with the European ophthalmology community. ... News
France 2030 supports KÔL’s clinical study in AMD Laboratoires KÔL has received French government funding under France 2030 to support SKY2, a clinical research programme dedicated to AMD. The study is evaluating aganirsen, an antisense oligonucleoti... Press
Corneal neovascularisation: KÔL reaches two new milestones KÔL reaches two new milestones in its commitment to rare eye diseases. Orphan drug designation (ODD) in Europe for the prevention of corneal graft rejection marks a first major step forward and highli... News
KÔL at SFO 2026 Three days of ophthalmology, meetings and discussions at the 132nd SFO International Congress, held in Paris from 9 to 11 May 2026. On this occasion, KÔL brought together Prof. Marc Muraine, Dr Serge ... News
KÔL x Kubota: a new partnership for patients with Stargardt disease KÔL is very proud to announce its collaboration with Kubota Vision Inc. through the signing of a supply and licence agreement to facilitate access in France to emixustat, a drug candidate for the trea... Press